GlassScriptPhysician profile
Ruth Dyal
NPI 1215927173
$621.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $106 · 2021: $71.48 · 2023: $25.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100.00 | 2019-2021 | |
| Therapeuticsmd, INC. | $91.39 | 2019 | |
| Hologic Sales and Service, LLC | $88.92 | 2019-2023 | Affirm Prone Biopsy System, Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $76.34 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $38.91 | 2019-2020 | |
| Millicent US INC | $34.56 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.28 | 2019 | |
| Exeltis, USA INC. | $32.14 | 2020-2021 | |
| Covidien LP | $23.20 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.07 | 2019 | |
| Duchesnay USA Incorporated | $18.42 | 2019 | |
| Avion Pharmaceuticals | $17.48 | 2021 | |
| Ascend Therapeutics US, LLC | $17.24 | 2021 | |
| Lupin INC. | $16.45 | 2019 | |
| Baxter Healthcare | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Dyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.